[go: up one dir, main page]

Pruzanski et al., 1970 - Google Patents

The significance of lysozyme (muramidase) in rheumatoid arthritis. I. Levels in serum and synovial fluid

Pruzanski et al., 1970

Document ID
2966453154731368995
Author
Pruzanski W
Saito S
Ogryzlo M
Publication year
Publication venue
Arthritis & rheumatism: official Journal of the American College of rheumatology

External Links

Snippet

Lysozyme (muramidase)* activity was estimated in 120 serum and 67 synovial fluid samples from patients with rheumatoid arthritis. These data were compared with the activity in samples from healthy controls and from patients with other forms of arthritis. In 35% of the …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/564Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Similar Documents

Publication Publication Date Title
Pruzanski et al. The significance of lysozyme (muramidase) in rheumatoid arthritis. I. Levels in serum and synovial fluid
AU560087B2 (en) Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4603106A (en) Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
West et al. Fibrotic healing of adult and late gestation fetal wounds correlates with increased hyaluronidase activity and removal of hyaluronan
US4822776A (en) Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
Meyer Mucoids and glycoproteins
Gallin et al. Efficacy of ascorbic acid in Chediak-Higashi syndrome (CHS): Studies in humans and mice
LaMont et al. Arachidonic acid stimulates mucin secretion in prairie dog gallbladder
Michelacci et al. Urinary excretion of glycosaminoglycans in normal and stone forming subjects
Fenton et al. Effect of glucosamine on interleukin‐1‐conditioned articular cartilage
Bhunchet et al. Contribution of immune response to the hepatic fibrosis induced by porcine serum
US6419927B1 (en) Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
Lai et al. Increased production of hyaluronan by peritoneal cells and its significance in patients on CAPD
TW201102653A (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
Pipkorn et al. Nasal mucosal mast cells and histamine in hay fever: effect of topical glucocorticoid treatment
Soto et al. Increased concentration of the complement split product C5a in acute pyelonephritis during pregnancy
HOW et al. T LYMPHOCYTE SENSITIZATION AND SUPPRESSOR T LYMPHOCYTE DEFECT IN PATIENTS LONG AFTER TREATMENT FOR GRAVES’DISEASE
US20120003178A1 (en) Evaluating the therapeutic potential of a glucan
Feiner et al. Bacterial lysis by lysozyme
Thompson et al. Familial defect of polymorph neutrophil phagocytosis associated with absence of a surface glycoprotein antigen (OKMI)
RU2759469C1 (en) Method for monitoring the effectiveness of antibiotic therapy in the treatment of acute pyelonephritis in infants
Ziff et al. Aminotripeptidase content of synovial fluid in arthritic diseases
Burnard et al. Beta‐endorphin levels in newborn cerebrospinal fluid
Bories et al. Up-regulation of nitric oxide production by interferon-γ in cultured peritoneal macrophages from patients with cirrhosis
Pruzanski et al. Lysozyme in rheumatic diseases